https://www.selleckchem.com/pr....oducts/thal-sns-032.
© 2020 The Authors. The Journal of Physiology © 2020 The Physiological Society.Therapeutic options for pulmonary arterial hypertension (PAH) have increased over the last decades. The advent of pharmacological therapies targeting the prostacyclin, endothelin and nitric oxide pathways have significantly improved outcomes. However, for the vast majority of patients, PAH remains a life limiting illness with no prospect of cure. PAH is characterized by pulmonary vascular remodelling. Current research focusses on targeting the underlying
Aimer
Commentaire
Partagez
